BIOMAT Database Logo BIOMAT Database Logo

Affordable inactivated poliovirus vaccine: strategies and progress. 2014

Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Polio Eradication Department, World Health Organization, Geneva, Switzerland.

After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use.

UI MeSH Term Description Entries
D011051 Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) Infantile Paralysis,Polio,Poliomyelitis, Nonpoliovirus,Poliomyelitis, Preparalytic,Encephalitis, Polio,Epidemic Acute Poliomyelitis,Polio Encephalitis,Poliomyelitis Infection,Poliomyelitis, Acute,Acute Poliomyelitis,Acute Poliomyelitis, Epidemic,Infection, Poliomyelitis,Infections, Poliomyelitis,Nonpoliovirus Poliomyelitis,Paralysis, Infantile,Poliomyelitides, Preparalytic,Poliomyelitis Infections,Poliomyelitis, Epidemic Acute,Polios,Preparalytic Poliomyelitis
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D003906 Developing Countries Countries in the process of change with economic growth, that is, an increase in production, per capita consumption, and income. The process of economic growth involves better utilization of natural and human resources, which results in a change in the social, political, and economic structures. LMICs,Less-Developed Countries,Low Income Countries,Low and Middle Income Countries,Lower-Middle-Income Country,Middle Income Countries,Third-World Countries,Under-Developed Countries,Developing Nations,Least Developed Countries,Less-Developed Nations,Third-World Nations,Under-Developed Nations,Countries, Middle Income,Countries, Third-World,Country, Least Developed,Country, Less-Developed,Country, Low Income,Country, Lower-Middle-Income,Country, Middle Income,Country, Third-World,Country, Under-Developed,Developed Country, Least,Developing Country,Developing Nation,Least Developed Country,Less Developed Countries,Less Developed Nations,Less-Developed Country,Less-Developed Nation,Low Income Country,Lower Middle Income Country,Lower-Middle-Income Countries,Middle Income Country,Nation, Less-Developed,Nation, Third-World,Nation, Under-Developed,Third World Countries,Third World Nations,Third-World Country,Third-World Nation,Under Developed Countries,Under Developed Nations,Under-Developed Country,Under-Developed Nation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014944 World Health Organization A specialized agency of the United Nations designed as a coordinating authority on international health work; its aim is to promote the attainment of the highest possible level of health by all peoples. Organization, World Health,WHO
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug
D060740 Disease Eradication Termination of all transmission of infection by global extermination of the infectious agent through surveillance and containment (From Porta, A Dictionary of Epidemiology, 5th ed). Disease Elimination,Disease Eliminations,Disease Eradications,Elimination, Disease,Eliminations, Disease,Eradication, Disease,Eradications, Disease

Related Publications

Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Inactivated poliovirus vaccine.
January 2007, Human vaccines,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
[Inactivated poliovirus vaccine].
September 2011, Nihon rinsho. Japanese journal of clinical medicine,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Inactivated poliovirus vaccine following oral poliovirus vaccine cessation.
April 2006, Releve epidemiologique hebdomadaire,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Enhanced inactivated poliovirus vaccine.
July 1994, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Change from oral poliovirus vaccine to inactivated poliovirus vaccine.
October 2002, Lancet (London, England),
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Efficacy and safety of oral poliovirus vaccine and inactivated poliovirus vaccine.
December 1991, The Pediatric infectious disease journal,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark.
January 1984, Reviews of infectious diseases,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Inactivated poliovirus vaccine in Finland.
January 1984, Reviews of infectious diseases,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Effectiveness of inactivated poliovirus vaccine.
November 2008, Current neurology and neuroscience reports,
Hiromasa Okayasu, and Roland W Sutter, and Hamid S Jafari, and Marina Takane, and R Bruce Aylward
Inactivated poliovirus vaccine and vaccine-associated paralytic poliomyelitis.
January 1997, JAMA,
Copied contents to your clipboard!